Biotechnology company Destiny Pharma reported wider losses on higher costs in the first half of the year. For the half-year ended 30 June 2020, pre-tax losses widened to £2.9m from £2.4m on-year. Administrative costs increased to £2.9m from £2.6m. Looking ahead, the company said it was well funded to complete the Phase 2 clinical development of its lead drug asset, XF-73. 'The company is currently designing the phase 3 clinical study that will hopefully follow,' it added. At 8:02am: (LON:DEST) Destiny Pharma Plc share price was 0p at 58p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.